FDA Clears Abbott Libre 2 and 3 Sensors for Use During MRI and CT Scans
The U.S. Food and Drug Administration (FDA) has cleared the Abbott Libre 2 and 3 sensors for use during most imaging procedures like MRIs and CT scans.
This is a big change, as people with diabetes using these devices previously had to remove them before scans, interrupting their glucose tracking.
Now, the FDA says these sensors can be safely worn in specific conditions.
“Abbott rigorously tested its FreeStyle Libre 2 and 3 systems sensors to ensure they remain effective after radiologic procedures. This testing led the FDA to clear the removal of the contraindication requirement, with no changes made to the sensor,” the company said in a statement.
Why This Is Important for People with Diabetes
Before this approval, there were concerns that the strong magnetic fields in MRI machines could harm the Libre sensors or make readings incorrect.
People with diabetes had to take off their sensors, missing out on important glucose data during medical tests.
With this clearance, Abbott’s Libre 2 and 3 sensors allow for continuous monitoring even in an MRI, under certain guidelines, providing peace of mind and uninterrupted glucose data.
Safety Tips for Patients
The new rules say that Libre 2 and 3 sensors can be used during MRIs with 1.5T or 3T strength scanners.
People with diabetes should talk with their doctor or radiologist before a scan to make sure it follows safety guidelines.
